Black Diamond Financial LLC Sells 198,660 Shares of Capricor Therapeutics, Inc. $CAPR

Key Points

• Black Diamond Financial LLC reduced its Capricor stake by 71.5% in Q4, selling 198,660 shares and leaving itself with 79,077 shares worth about $2.28 million (≈0.17% of the company).
• Company insiders have been active sellers—CFO Anthony Bergmann sold 25,000 shares and a director sold 61,265 shares, with insiders disposing of a total of 172,529 shares (~$5.3M) in the past 90 days (insiders own 9.2%).
• Shares trade around $33.94 with a 52-week range of $4.30–$40.37 and a market cap of ~$1.96B, and analysts show optimism: consensus is a "Moderate Buy" with an average target of $46.09 and several firms issuing $58–$63 targets.

Black Diamond Financial LLC cut its holdings in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 71.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 79,077 shares of the biotechnology company's stock after selling 198,660 shares during the period. Black Diamond Financial LLC owned approximately 0.17% of Capricor Therapeutics worth $2,282,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Farther Finance Advisors LLC bought a new position in shares of Capricor Therapeutics in the 3rd quarter worth about $28,000. Parkside Financial Bank & Trust bought a new position in shares of Capricor Therapeutics in the 3rd quarter worth about $36,000. Russell Investments Group Ltd. raised its position in shares of Capricor Therapeutics by 122.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company's stock worth $37,000 after acquiring an additional 2,786 shares in the last quarter. GoalVest Advisory LLC bought a new position in shares of Capricor Therapeutics in the 4th quarter worth about $59,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of Capricor Therapeutics by 280.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company's stock valued at $67,000 after buying an additional 4,976 shares during the period. 21.68% of the stock is owned by institutional investors.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR opened at $33.94 on Friday. Capricor Therapeutics, Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $40.37. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of -15.02 and a beta of 0.48. The firm's 50-day simple moving average is $31.45 and its 200 day simple moving average is $23.34.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). On average, sell-side analysts predict that Capricor Therapeutics, Inc. will post 0.01 EPS for the current year.

Analyst Upgrades and Downgrades

CAPR has been the subject of several research reports. B. Riley Financial raised their target price on Capricor Therapeutics from $50.00 to $63.00 and gave the company a "buy" rating in a research note on Friday, March 13th. Cantor Fitzgerald set a $62.00 target price on Capricor Therapeutics and gave the company an "overweight" rating in a research note on Friday, March 13th. HC Wainwright restated a "buy" rating and issued a $60.00 target price on shares of Capricor Therapeutics in a research note on Tuesday, March 10th. Wall Street Zen downgraded Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, January 11th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Capricor Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $46.09.

Insider Activity

In related news, CFO Anthony Bergmann sold 25,000 shares of the firm's stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $30.13, for a total value of $753,250.00. Following the transaction, the chief financial officer owned 8,223 shares of the company's stock, valued at approximately $247,758.99. This trade represents a 75.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Karimah Es Sabar sold 61,265 shares of the firm's stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $30.17, for a total transaction of $1,848,365.05. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 172,529 shares of company stock worth $5,302,440. 9.20% of the stock is owned by insiders.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.